CDTX Cidara Therapeutics

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below investor conferences.

Event: RBC Global Healthcare Conference

Date: Wednesday, May 21, 2025

Time: 10:00 AM ET

Event: Jefferies Global Healthcare Conference

Date: Wednesday, June 4, 2025

Time: 11:40 AM ET

The live webcast for the presentations can be accessed in the Investors section on the Company’s website at /investors/events/. Replays of the presentations will be available for at least 30 days.

Cidara will also participate in one-on-one investor meetings during these events.

About Cidara Therapeutics

Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of Phase 2b enrollment in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit .

INVESTOR CONTACT:

Brian Ritchie

LifeSci Advisors

(212) 915-2578

MEDIA CONTACT:

Michael Fitzhugh

LifeSci Communications

 



EN
13/05/2025

Underlying

CDTXCidara Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cidara Therapeutics

 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Announces Closing of Upsized Public Offering and Full Exercise ...

Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the closing of its underwritten public offering of 9,147,727 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,193,181 shares, at a price to the public of $44.00 per sh...

June 26, 2025 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Announces Pricing of Upsized Public Offering of Common Stock

Cidara Announces Pricing of Upsized Public Offering of Common Stock SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the pricing of an underwritten public offering of 7,954,546 shares of its common stock at a price to the public of $44.00 per share. All of the shares are to be sold by Cidara. The gross proceeds to Cidara from the offering, before deducting underwriting discounts and commissions and offering ex...

June 25, 2025 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Announces Proposed Public Offering of Common Stock

Cidara Announces Proposed Public Offering of Common Stock SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $250.0 million of shares of its common stock. All of the shares are being offered by Cidara. In connection with the proposed offering, Cidara expects to grant the underwriters a 30-day option to...

June 23, 2025 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics Announces Positive Topline Results from its Phase ...

Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza The study met its primary and all secondary efficacy endpoints for all dose groups Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo CD388 was well-tolerated with no safety signals observed End of Phase 2 meeting request has been submitted to the U.S. Food and Drug Administration (FDA) Cidara will host a conference...

June 23, 2025 1 EN
Free Trial
CDTX Cidara Therapeu...

Cidara Therapeutics Inc: 1 director

A director at Cidara Therapeutics Inc maiden bought 3,320 shares at 22.258USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...

CDTX CIDARA THERAPEUTICS
06/05/25 June 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch